Stem Cell Media Interview With Dr. Adrian Harel: Fighting to End ALS,
Once and for All
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 12/04/12 --
Sai Rosen of www.InvestorStemCell.com (Stem Cell Media, LLC)
recently sat down with Dr. Adrian Harel, Chief Executive Officer for
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI). Brainstorm Cell
Therapeutics Inc. is a biotechnology company developing autologous
stem cell therapies for highly debilitating neurodegenerative
disorders, such as Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's
disease), Multiple Sclerosis (MS) and Parkinson's disease (PD) and
Spinal Cord Injury. These diseases have limited treatment options and
as such represent unmet medical needs.
Dr. Harel has over 30 years' experience in international business
development, marketing, clinical development, fund raising and
building strategic partnerships. In January 2011, he came to
Brainstorm and leveraged all his experience to transform the company
from a struggling pre-clinical biotech to the world's leader in
clinical stage neurodegenerative treatment for ALS. The company is
nearing submission of an ALS Phase II, to be conducted at the
renowned Massachusetts General Hospital (MGH).
During his interview, Dr. Harel shared the following information:
Why are you interested in neurodegenerative disorders?
Dr. Harel: "I became fascinated in this area of research while
working at Proneuron Biotechnologies. We had created the 'world
center' for paralysis. I had the pleasure to work with Christopher
Reeve and other clinical leaders. We pioneered these early stage
cellular treatments and I was pleased to have played a significant
role in regulatory and managing endeavors across multiple channels
both internal and external."
What brought you to Brainstorm?
Dr. Harel: "I have spent my whole life helping others, working with
teams that are inspired to find solutions to difficult biological
problems with the end goal to ease the burden of suffering. ALS is in
my opinion the worst of the worst when considering unmet
neurodegenerative diseases. I believe our data from the ALS Phase I
is showing measurable improvements in key areas of those afflicted
and may be proven to be a treatment for ALS."
What is the credit market
Dr. Harel: "It has been difficult to engage in terms that are not
burdensome to goals. It is a fine line to ensure solvency, manage
dilution and move our clinical trials forward as expeditiously as
possible. I was able to arrange favorable terms early this summer and
closed in July on a $5.7 million Public Offering. We have been
successful with securing non-dilutive grants. Since coming to
Brainstorm in January, I have raised over $10 million."
What is next for Brainstorm?
Dr. Harel: "We concluded our ALS Phase I trial in Israel recently. We
are nearing filing with the FDA a Phase II ALS trial to be conducted
at MGH in Boston. We are progressing and we are pleased with the
initial safety and efficacy we are seeing. I anticipate beginning the
trial at MGH in early 2013."
What would you say to those living with ALS?
Dr. Harel: "I wake up every day with the charge to end ALS. I will
not rest and I will not give up until I find a viable cellular
solution for treatment and a disease reversal leading to a cure. I am
excited about the data we have. Very few companies are working
towards a treatment for ALS and that makes me work even harder
knowing that so many are depending on us."
Do you see a time when ALS will be no more?
Dr. Harel: "Simply put, yes! We are working with the best researchers
and clinicians in Israel and soon to be working with the best in the
USA. I am not giving up."
Sai Rose concluded, "In my years of interviewing CEOs of companies, I
have never met a more passionate CEO than Dr. Harel. He has the
entire skill set package that is needed to succeed and grow a
clinical stage company."
About Stem Cell Media, LLC.
Stem Cell Media, LLC. (SCM) is the world's 1st and only media company
dedicated to the regenerative medicine sector.
www.Investorstemcell.com is an online social media forum dedicated to
investors interested in public companies using stem cells.
Stem Cell Media, LLC.
Press spacebar to pause and continue. Press esc to stop.